JP2025504431A - レンチウイルスベースの経鼻ワクチンによるＳＡＲＳ－ＣｏＶ－２免疫のブースト - Google Patents

レンチウイルスベースの経鼻ワクチンによるＳＡＲＳ－ＣｏＶ－２免疫のブースト Download PDF

Info

Publication number
JP2025504431A
JP2025504431A JP2024542183A JP2024542183A JP2025504431A JP 2025504431 A JP2025504431 A JP 2025504431A JP 2024542183 A JP2024542183 A JP 2024542183A JP 2024542183 A JP2024542183 A JP 2024542183A JP 2025504431 A JP2025504431 A JP 2025504431A
Authority
JP
Japan
Prior art keywords
cov
protein
sars
residue
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024542183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504431A5 (enExample
Inventor
ピエール・シャルノー
ラレー・マジレッシ
マリリーヌ・ブルジーヌ
ベンジャミン・ヴェシン
ジョディ・ロペス
イングリッド・フェール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravectys SA
Original Assignee
Theravectys SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravectys SA filed Critical Theravectys SA
Publication of JP2025504431A publication Critical patent/JP2025504431A/ja
Publication of JP2025504431A5 publication Critical patent/JP2025504431A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024542183A 2022-01-17 2023-01-17 レンチウイルスベースの経鼻ワクチンによるＳＡＲＳ－ＣｏＶ－２免疫のブースト Pending JP2025504431A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2022/000035 2022-01-17
PCT/IB2022/000035 WO2023135439A1 (en) 2022-01-17 2022-01-17 Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine
PCT/EP2023/051025 WO2023135333A1 (en) 2022-01-17 2023-01-17 Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine

Publications (2)

Publication Number Publication Date
JP2025504431A true JP2025504431A (ja) 2025-02-12
JP2025504431A5 JP2025504431A5 (enExample) 2026-01-27

Family

ID=80787107

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024542183A Pending JP2025504431A (ja) 2022-01-17 2023-01-17 レンチウイルスベースの経鼻ワクチンによるＳＡＲＳ－ＣｏＶ－２免疫のブースト

Country Status (9)

Country Link
US (1) US20250090655A1 (enExample)
EP (1) EP4466015A1 (enExample)
JP (1) JP2025504431A (enExample)
KR (1) KR20240135619A (enExample)
CN (1) CN118829444A (enExample)
AU (1) AU2023207825A1 (enExample)
CA (1) CA3242669A1 (enExample)
TW (1) TW202337492A (enExample)
WO (2) WO2023135439A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
WO2024050483A1 (en) * 2022-08-31 2024-03-07 Modernatx, Inc. Variant strain-based coronavirus vaccines and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220152248A (ko) * 2020-03-13 2022-11-15 옥스포드 유니버시티 이노베이션 리미티드 면역 반응을 유도하기 위한 조성물 및 방법
JP2023535163A (ja) * 2020-07-15 2023-08-16 アンスティテュ・パストゥール Ｓａｒｓ－ｃｏｖ－２免疫原性組成物、ワクチン、及び方法
CN117120085A (zh) * 2020-07-15 2023-11-24 巴斯德研究所 Sars-cov-2免疫原性组合物、疫苗和方法
WO2022167831A1 (en) * 2021-02-02 2022-08-11 Institut Pasteur Sars-cov-2 immunogenic compositions, vaccines, and methods

Also Published As

Publication number Publication date
CN118829444A (zh) 2024-10-22
AU2023207825A9 (en) 2024-08-15
KR20240135619A (ko) 2024-09-11
CA3242669A1 (en) 2023-07-20
US20250090655A1 (en) 2025-03-20
WO2023135333A1 (en) 2023-07-20
AU2023207825A1 (en) 2024-08-08
WO2023135439A1 (en) 2023-07-20
EP4466015A1 (en) 2024-11-27
TW202337492A (zh) 2023-10-01

Similar Documents

Publication Publication Date Title
US20230021583A1 (en) Measles-vectored covid-19 immunogenic compositions and vaccines
US20240131154A1 (en) Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus
CA2311647C (en) Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination
Law et al. SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1
KR20230025670A (ko) Sars-cov-2 백신
JP7788403B2 (ja) 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン
WO2021173829A1 (en) Vaccines against coronavirus and methods of use
Yao et al. Virus-like particle and DNA-based candidate AIDS vaccines
US20230256084A1 (en) Sars-cov-2 immunogenic compositions, vaccines, and methods
US20250090655A1 (en) Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine
CN119233982A (zh) 包含免疫应答增强基因的双顺反子lamp构建体及其使用方法
Tohidi et al. Induction of a robust humoral response using HIV-1 VLPMPER-V3 as a novel candidate vaccine in BALB/C mice
Moliva et al. Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates
Moriya et al. Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies
US20240010739A1 (en) Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes
CN117730150A (zh) 用于诱导对SARS-CoV-2的特异性免疫的冻干形式的药剂（变体）
US20250090653A1 (en) Sars cov-2 vaccine, associated polynucleotides, and methods of use
EP4333887A1 (en) Vaccines against coronavirus and methods of use
WO2022167831A1 (en) Sars-cov-2 immunogenic compositions, vaccines, and methods
US20250325657A1 (en) Modified vaccinia ankara (mva) vaccine
WO2013126469A1 (en) Chimeric dna vaccine compositions and methods of use
Frantz et al. A measles-vectored COVID-19 vaccine induces long-term immunity and protection from SARS-CoV-2 challenge in mice
García-Arriaza et al. MVA-based vaccine against COVID-19 expressing SARS-CoV-2 antigens
CN117479953A (zh) 针对冠状病毒的疫苗及其使用方法
Reed et al. Design and immunogenicity of a Pan-SARS-CoV-2 synthetic DNA vaccine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260116